Epigral Ltd Stock Falls to 52-Week Low of Rs.1045.55 Amid Continued Downtrend

Recent Price Movement and Market Context

On 27 Jan 2026, Epigral Ltd’s share price slipped to Rs.1045.55, down 0.62% on the day, underperforming the Specialty Chemicals sector by 0.27%. This decline extends a two-day losing streak during which the stock has fallen by 3.1%. Notably, the share price is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum.

The broader market environment has also been challenging. The Sensex opened lower by 100.91 points and currently trades at 81,409.61, down 0.16%. The index has experienced a three-week consecutive decline, losing 2.59% over this period. Additionally, other indices such as NIFTY MEDIA and NIFTY REALTY also hit new 52-week lows today, indicating sector-wide pressures.

Long-Term Performance and Valuation Metrics

Epigral Ltd’s one-year performance has been notably weak, with a return of -40.50%, starkly contrasting with the Sensex’s positive 8.00% gain over the same period. The stock’s 52-week high was Rs.2114.30, highlighting the extent of the recent decline. Over the last five years, the company’s operating profit has contracted at an annual rate of -5.49%, reflecting subdued growth trends.

Financially, the company’s Mojo Score stands at 31.0, with a current Mojo Grade of Sell, upgraded from a previous Strong Sell as of 26 Dec 2025. The Market Cap Grade is rated 3, indicating moderate market capitalisation relative to peers.

Quarterly Financial Results and Profitability Trends

The company’s recent quarterly results have shown a decline in profitability. Profit Before Tax excluding other income (PBT LESS OI) for the quarter stood at Rs.67.91 crores, down 45.2% compared to the previous four-quarter average. Similarly, Profit After Tax (PAT) for the quarter was Rs.51.22 crores, reflecting a 52.6% decrease against the prior four-quarter average. These figures underscore a contraction in earnings in the near term.

Interest expenses for the nine-month period have increased by 37.3%, reaching Rs.56.98 crores, which may exert additional pressure on net profitability going forward.

Comparative Performance and Market Position

Epigral Ltd has underperformed the BSE500 index over multiple time frames, including the last three years, one year, and three months. This consistent underperformance highlights challenges in maintaining competitive growth and market share within the Specialty Chemicals sector.

Despite these headwinds, the company demonstrates strong management efficiency, reflected in a high Return on Capital Employed (ROCE) of 23.19%. This indicates effective utilisation of capital resources relative to earnings generation.

Debt servicing capacity remains robust, with a low Debt to EBITDA ratio of 1.34 times, suggesting manageable leverage levels and financial stability in servicing obligations.

Valuation and Peer Comparison

Epigral Ltd’s valuation metrics present a mixed picture. The company’s ROCE of 19.3% is accompanied by an enterprise value to capital employed ratio of 2, which is considered very attractive. The stock currently trades at a discount relative to its peers’ average historical valuations, potentially reflecting market concerns over recent earnings volatility.

Interestingly, while the stock has generated a negative return of -40.50% over the past year, its profits have risen by 37.1% during the same period, resulting in a low PEG ratio of 0.4. This divergence between price performance and profit growth may indicate market caution or other underlying factors influencing investor sentiment.

Shareholding and Corporate Structure

The majority shareholding in Epigral Ltd is held by promoters, indicating concentrated ownership. This structure often allows for strategic decision-making aligned with long-term corporate objectives.

Overall, the stock’s recent decline to a 52-week low of Rs.1045.55 reflects a combination of subdued earnings performance, increased interest costs, and broader market pressures. While the company maintains strong capital efficiency and manageable debt levels, the price action highlights investor caution amid ongoing challenges in growth and profitability.

Market and Sector Overview

The Specialty Chemicals sector, to which Epigral Ltd belongs, has faced headwinds in recent sessions, with multiple indices hitting new lows. The Sensex’s current position below its 50-day moving average, despite the 50DMA remaining above the 200DMA, suggests a cautious market environment. This backdrop has contributed to the downward pressure on stocks like Epigral Ltd.

Summary of Key Metrics

To summarise, Epigral Ltd’s key financial and market metrics as of 27 Jan 2026 are:

• New 52-week low price: Rs.1045.55


• One-year stock return: -40.50%


• Sensex one-year return: +8.00%


• Operating profit CAGR (5 years): -5.49%


• Quarterly PBT LESS OI: Rs.67.91 crores (-45.2%)


• Quarterly PAT: Rs.51.22 crores (-52.6%)


• Interest expense (9 months): Rs.56.98 crores (+37.3%)


• ROCE: 23.19%


• Debt to EBITDA ratio: 1.34 times


• PEG ratio: 0.4

These figures provide a comprehensive view of the company’s current financial health and market standing.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →